The Institut Bordet Medical Oncology Clinic has a number of roles:
- diagnosis and therapeutic care of patients with solid tumours
- overseeing administration of cancer medication for in-patients and out-patients
- monitoring patients during and after their treatment.
The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.
The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.
The Medical Oncology Clinic is divided into 12 sectors:
- thoracic oncology
- urogenital oncology
- breast oncology
- innovative treatments
- endocrine tumour oncology
- bone and soft tissue tumour oncology
- gynaecological oncology
- digestive oncology
- cervico-facial oncology
- skin tumour oncology
- central nervous system oncology.
The Medical Oncology Clinic works in close collaboration with the Institut Bordet Clinical Trials Conduct Unit (CTCU). This unit, which is responsible for the development of new drugs and innovative approaches to care, handles phase I, II and III clinical studies in tumours. The CTCU is made up of research nurses, clinical research associates and data managers who, with research doctors, closely monitor patients taking part in clinical trials.
The Institut’s different research laboratories are also closely linked to the Medical Oncology Clinic. Their principal aim is to identify predictive marker molecules (indicating probability of response to a given treatment) and/or prognosis (chances of a cure) as part of the development of breast cancer treatments.
Recently, the Oncodistinct research network was created. This network brings together numerous researchers who share a common vision of innovative clinical research. The aim of the network is to accelerate the personalisation of treatment and the development of innovative treatments while also promoting a multidisciplinary approach to research and care.
Below, among others, some studies :
The Institut Bordet Medical Oncology Clinic plays an important role in education, both in Belgium and abroad. Within the hospital, the Clinic’s medical team supervises the training of young doctors and medical students specialising in oncology. Always keen to promote quality training, the Clinic also welcomes many doctors from abroad as part of its Fellowship Programme.
AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.
CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS.
- Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
- Collaborations :
- Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
- Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
- Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility
ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
- Project leader : Philippe Aftimos
- Collaborations : International clinical study
- Funding (or) Support : Zenith Epigenetics Ltd.
Head of the Medical Oncology Clinic
Pr A. Awada
Pr M. Piccart, Dr D. de Valeriola
Dr Ph. Aftimos, Dr A. Gombos
Pr Ch. Sotiriou, Dr E. de Azambuja
Dr M. Ignatiadis, Dr F. Lebrun
Dr L. Buisseret, Dr L. Polastro
Pr A. Drowart, Dr D. t’Kint de Roodenbeke
Dr M. Hanappe
Dr D. t’Kint de Roodenbeke
Dr S. Luce
Pr D. Razavi
Pr J. Klastersky (internal medicine/oncology)
Dr A. Deleporte (digestive oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr J. Kerger (oncologie gynécologique/cutanée)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Dr L. Mans (digestive oncology)
Dr H. Rouvière (geriatry)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)
Dr Y. Wissam (medical oncology)
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
Authors : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772
ASO Visual Abstract: The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases-A Pilot Study.
Authors : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Year : 2023
Journal : Ann Surg Oncol
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Authors : Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, OShaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart-Gebhart M
Year : 2023
Journal : Eur J Cancer
Volume : 178
Pages : 23-33
PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Authors : Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A
Year : 2023
Journal : Lancet Haematol